Offered by: Nemours
Location: Delaware Valley, Jacksonville, FL
Phase I Traditional 3+3 Trial of PO Sorafenib in Refractory or Recurrent Pediatric Solid Malignancies
View on Clinicaltrials.gov »
What is the trial about?
To establish the safest doses of Topotecan and Sorafenib when given together to children whose tumors have not responded to treatment or whose tumors have come back despite treatment.
Who can participate?
Age >3 years and ≤18 years of age at the time of study entry.
What is involved?
- Your child’s involvement will last for approximately 24 months. The first evaluation of the response to the medications will be after 2 cycles (2 months).
- Prior to and during each cycle your child will be evaluated by physical exam, blood pressure, and lab tests. You will be asked to complete a daily medication diary. Scans for tumor measurement will be done every 2 cycles.